ISIS (ISIS)
$175m ($26.25m) 144a unsec sr cb pricing TUE nite from GS, JPM, BARCAP. Terms: 7 yr, 3-3.75% up 27.5-32.5%, nc-4, 130% after, prot. UOP= GCP and repurchase of existing 2.625% converts. ISIS focuses on developing antisense drugs for cardiovascular, inflammatory and metabolic diseases. Co has handful of its pipeline licensed or partnered w/larger pharmas. Has 8 drugs in phase 2 dev and 2 in phase 3. We’re using L+300 for the old ones, will use L+650 for 7 yr. 90d IV 50/10 ile = 41.4/25.3. We’ll use 35 to dscnt for duration. Using 50 bos brw, theo = 102.5/104.625/106.875. 2.625 have been hot recently, sector in favor and with UOP mentioning potential call of old, we’d expect a rotation into the new. Definate reprice potential here as this is as BUY.